| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 67591 |
Ad-PG-FA 线性聚缩水甘油修饰叶酸靶向分子 |
75 |
h |
2024-12-18 |
| 67592 |
三嵌段共聚物PCL-PEEGE-PCL |
153 |
h |
2024-12-18 |
| 67593 |
炔基功能化的聚乙二醇(alkynyl-PEG) |
54 |
h |
2024-12-18 |
| 67594 |
cas:784105-33-5，Amino-PEG3-C2-acid，3-[2-[2-(2-氨基乙氧基)乙氧基]乙氧基]丙酸 |
76 |
kx |
2024-12-18 |
| 67595 |
Phthalamidoxy-PEG2-CH2-ald，cas:1415246-44-4 |
65 |
zyl |
2024-12-18 |
| 67596 |
甘草次酸偶联Gd-DOTA(GGD) |
56 |
h |
2024-12-18 |
| 67597 |
Fmoc-NH-PEG6-CH2COOH，cas:437655-96-4 |
56 |
zyl |
2024-12-18 |
| 67598 |
cas:557756-85-1，Fmoc-NH-PEG4-CH2CH2COOH，5,8,11,14-四氧杂-2-氮杂十七烷二酸1-(9H-芴-9-基甲基)酯 |
79 |
kx |
2024-12-18 |
| 67599 |
DOTA-3-酪氨酰基-奥曲肽 DOTA-TATE |
67 |
h |
2024-12-18 |
| 67600 |
DBCO-DOTA-Eu 叠氮功能化修饰OTA-Eu |
151 |
h |
2024-12-18 |
| 67601 |
HO-PEG10-CH2COOtBu |
70 |
zyl |
2024-12-18 |
| 67602 |
cas:1026987-94-9，DUPA(OtBu)-OH |
66 |
kx |
2024-12-18 |
| 67603 |
NOTA/DFO-MAL-Cys-MZHER2 亲和体Cys-MZHER2偶联螯合剂NOTA/DFO-MAL |
75 |
h |
2024-12-18 |
| 67604 |
N-DBCO-N-bis(PEG2-amide-PEG4-Val-Cit-PAB-MMAE) |
76 |
WYQ |
2024-12-18 |
| 67605 |
Propargyl-PEG2-CH2CO2-NHS ester，cas:2244145-13-7 |
73 |
zyl |
2024-12-18 |
| 67606 |
NHS ester-PEG4-Val-Cit-PAB-MMAE，（二苯并环辛炔N-羟基琥珀酰亚胺酯） |
151 |
WYQ |
2024-12-18 |
| 67607 |
1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸-1-柰丙氨酸-奥曲肽 DOTA-NOC |
68 |
h |
2024-12-18 |
| 67608 |
CAS号为1350456-56-2的Fmoc-Val-Cit-PAB-MMAE |
58 |
WYQ |
2024-12-18 |
| 67609 |
Azido-PEG3-CH2CO2Me，cas:1253389-31-9 |
61 |
zyl |
2024-12-18 |
| 67610 |
cas:60444-78-2，Ald-Ph-NHS ester，4-甲酰苯甲酸N-琥珀酰亚胺酯 |
118 |
kx |
2024-12-18 |
| 67611 |
荧光染料sulfo-Cy5.5-NHS酯 |
101 |
h |
2024-12-18 |
| 67612 |
DOTA-NVVRQ DOTA-TMTP1 双功能螯合剂DOTA偶联多肽TMTP1(NVVRQ) |
80 |
h |
2024-12-18 |
| 67613 |
CAS号为2353409-69-3的Mal-PEG8-Val-Cit-PAB-MMAE |
85 |
WYQ |
2024-12-18 |
| 67614 |
聚DOTA新型树枝状分子(PDOTA) |
89 |
h |
2024-12-18 |
| 67615 |
Anti-EGFR (cetuximab)-EDC/NHS-methotrexate |
138 |
kx |
2024-12-18 |
| 67616 |
CAS号为646502-53-6的MC-Val-Cit-PAB-MMAE |
125 |
WYQ |
2024-12-18 |
| 67617 |
介孔硅纳米粒子(MSNs) |
165 |
h |
2024-12-18 |
| 67618 |
DO3A-Ether-Rhein 10-{[6-(1,8-二羟基蒽醌-3-甲酰氨基)乙氧基乙基]氨基}羰酰甲基-1,4,7,10-四氮杂环十二烷-1,4,7-三乙酸 |
85 |
h |
2024-12-18 |
| 67619 |
MC-Val-Cit-PAB-MMAF（或简写为Vc-MMAF） |
88 |
WYQ |
2024-12-18 |
| 67620 |
Anti-CD33 (h2H12ec)-Mc-VC-SGD-1882， ADC试剂 |
98 |
kx |
2024-12-18 |
| 67621 |
FITC-cNGR 绿色荧光素FITC标记cNGR环状 |
87 |
h |
2024-12-18 |
| 67622 |
Azide-PEG3-Val-Cit-PAB-MMAF，叠氮-三聚乙二醇-Val-Cit-PAB-MMAF |
77 |
WYQ |
2024-12-18 |
| 67623 |
cas:2454675-51-3，t-butyl-C18-D-Glu-OtBu，ADC定制 |
90 |
wyh |
2024-12-18 |
| 67624 |
包裹瑞喹莫德的PS脂质体（PS-R848）,包裹R848的PS仿生脂质体 |
167 |
axc |
2024-12-18 |
| 67625 |
MC-Val-Cit-Doxorubicin（CAS号：159857-70-2） |
76 |
WYQ |
2024-12-18 |
| 67626 |
Anti-CD22 (clone G5/44)-AcBut-CalichDMH，ADC定制 |
73 |
kx |
2024-12-18 |
| 67627 |
cas:870487-07-3，Fmoc-Lys(Boc)-PAB-PNP，ADC定制 |
75 |
wyh |
2024-12-18 |
| 67628 |
cas:2055042-67-4，Azido-PEG4-Ala-Ala-Asn(Trt)-PAB，ADC定制 |
102 |
wyh |
2024-12-18 |
| 67629 |
蜚蠊提取物长效脂质体,CE-Lip,靶向脂质体定制服务 |
119 |
axc |
2024-12-18 |
| 67630 |
cas:150114-97-9，Fmoc-Val-Ala-OH ，Fmoc-L-缬氨酰-L-丙氨酸 |
83 |
kx |
2024-12-18 |
| 67631 |
Biotin-PEG11-Gly-Gly-Gly-Amine，生物素-PEG11-甘氨酸三肽-胺，ADC定制 |
60 |
wyh |
2024-12-18 |
| 67632 |
Azido-PEG4-Val-Ala-PAB-PNP，由叠氮基团（-N3）、PEG4、Val、Ala、PAB和PNP组成 |
116 |
WYQ |
2024-12-18 |
| 67633 |
三分枝脂质体配体,3RGD-Chol,提供荧光脂质体定制服务 |
102 |
axc |
2024-12-18 |
| 67634 |
cas:1343476-44-7，Val-Ala-PAB-OH ， ADC试剂 |
75 |
kx |
2024-12-18 |
| 67635 |
cas:28320-73-2，Boc-Gly-Gly-Gly-OH，ADC定制 |
109 |
wyh |
2024-12-18 |
齐岳微信公众号
官方微信
库存查询